Stockwatch: Full-Year 2020 Guidance Separates Novartis And Roche
Swiss Pharma’s Reputation For Financial Conservatism Could Suffer If Guidance Keeps Underplaying Pandemic Pressures
Executive Summary
Pandemic-related clinic closures and safety issues forced Novartis to trim its guidance slightly. But Roche, faced with more severe pandemic and biosimilar pressures, left January’s guidance unchanged.